GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Egyptian International Pharmaceutical Investments (CAI:PHAR) » Definitions » Return-on-Tangible-Asset

Egyptian International Pharmaceutical Investments (CAI:PHAR) Return-on-Tangible-Asset : 20.21% (As of Mar. 2024)


View and export this data going back to 1995. Start your Free Trial

What is Egyptian International Pharmaceutical Investments Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Egyptian International Pharmaceutical Investments's annualized Net Income for the quarter that ended in Mar. 2024 was E£2,330 Mil. Egyptian International Pharmaceutical Investments's average total tangible assets for the quarter that ended in Mar. 2024 was E£11,530 Mil. Therefore, Egyptian International Pharmaceutical Investments's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 was 20.21%.

The historical rank and industry rank for Egyptian International Pharmaceutical Investments's Return-on-Tangible-Asset or its related term are showing as below:

CAI:PHAR' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 9.51   Med: 14.24   Max: 22.74
Current: 12.43

During the past 13 years, Egyptian International Pharmaceutical Investments's highest Return-on-Tangible-Asset was 22.74%. The lowest was 9.51%. And the median was 14.24%.

CAI:PHAR's Return-on-Tangible-Asset is ranked better than
80.78% of 1082 companies
in the Drug Manufacturers industry
Industry Median: 1.685 vs CAI:PHAR: 12.43

Egyptian International Pharmaceutical Investments Return-on-Tangible-Asset Historical Data

The historical data trend for Egyptian International Pharmaceutical Investments's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Egyptian International Pharmaceutical Investments Return-on-Tangible-Asset Chart

Egyptian International Pharmaceutical Investments Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.21 10.32 9.51 10.72 9.83

Egyptian International Pharmaceutical Investments Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.74 13.77 4.53 10.33 20.21

Competitive Comparison of Egyptian International Pharmaceutical Investments's Return-on-Tangible-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Egyptian International Pharmaceutical Investments's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Egyptian International Pharmaceutical Investments's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Egyptian International Pharmaceutical Investments's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Egyptian International Pharmaceutical Investments's Return-on-Tangible-Asset falls into.



Egyptian International Pharmaceutical Investments Return-on-Tangible-Asset Calculation

Egyptian International Pharmaceutical Investments's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=823.306/( (6772.343+9976.481)/ 2 )
=823.306/8374.412
=9.83 %

Egyptian International Pharmaceutical Investments's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=2330.084/( (9976.481+13082.54)/ 2 )
=2330.084/11529.5105
=20.21 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data.


Egyptian International Pharmaceutical Investments  (CAI:PHAR) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Egyptian International Pharmaceutical Investments Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Egyptian International Pharmaceutical Investments's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Egyptian International Pharmaceutical Investments (CAI:PHAR) Business Description

Traded in Other Exchanges
N/A
Address
1st Industrial Zone B1, EIPICO, 10th of Ramadan, EGY
Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, non-traditional dosage forms including soft gelatin capsules, lyophilized products, gels, sprayers and effervescent tablets. It exports its products to Arab countries, African, Asian and East European Countries. Its products portfolio includes antibiotics, anesthetics, analgesics, antihypertensives, cholesterol-lowering medications, ophthalmic products, blood substitutes and restoratives, dermatological drugs and vitamins. Some of its products are Vasotec, Co-vasotec, Flumox, and Cefotax.